New incident report
Incident Report Number: 2019-6280
Registrant Reference Number: 2019-US-023219
Registrant Name (Full Legal Name no abbreviations): The Hartz Mountain Corporation
Address: 400 Plaza Drive
City: Secaucus
Prov / State: New Jersey
Country: USA
Postal Code: 07094-3688
Domestic Animal
Country: UNITED STATES
Prov / State: PENNSYLVANIA
PMRA Registration No. PMRA Submission No. EPA Registration No. 2596-83
Product Name: Hartz UltraGuard Flea and Tick Collar for Cats and Kittens
Other (specify)
CollarYes
Unknown
Site: Animal / Usage sur un animal domestique
Unknown
Animal's Owner
Cat / Chat
Unknown
1
Female
1
Unknown
Skin
Unknown / Inconnu
Unknown / Inconnu
System
Persisted until death
No
No
Died
Treatment / Traitement
(eg. description of the frequency and severity of the symptoms
On an unknown date in 2018, the pet owner applied one Hartz UltraGuard Flea and Tick Collar for Cats and Kittens (Tetrachlorvinphos) to the cat. On 23-Jul-2018 the cat died. No other clinical signs prior to death were reported. The owner reported that no cause of death was determined but did not specify if a necropsy was performed. No further information was received in this case.
Death
Assessment: This product is considered to have a wide margin of safety in cats. If a small amount of product was ingested, only minor oral irritation or gastrointestinal upset resulting in drooling of vomiting would be expected. Sudden death is not expected and not likely due to product use. Other causes including unknown trauma, underlying congenital conditions, metabolic diseases, cardiac disease and aortic thromboembolism (saddle thrombus) should be considered. The information contained in this report is based on self-reported statements provided to the registrant during telephone Interview(s). These self-reported descriptions of an incident have not been independently verified to be factually correct or complete descriptions of the incident. For that reason, information contained in this report does not and cannot form the basis for a determination of whether the reported clinical effects are causally related to exposure to the product identified in the telephone interviews.